65,437 trials
SARS-CoV-2
Primary: Number of Participants With Solicited Local and Systemic ARs — 270; 554; 113; 290 Participants
Diabetes Mellitus, Type 2
Primary: Glycated Hemoglobin (HbA1C) — 9; 9.1; 7.7; 7.6 Percentage of HbA1c
Non-squamous, Non-Small Cell Lung Cancer
Primary: Time on Treatment of Afatinib as First-line Therapy in Advanced Non-small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Mutation — 14.4 Months
Plasma Cell Neoplasm
Primary: Seroprotection Based on Hemagglutination Antibody Inhibition (HAI) — 32; 22 Participants
Car Seat Installation
Primary: Percentage of Inspection Points Correctly Installed From Pre Installation to Post Installation — 95.78; 97.33 percentage of inspection points — p=0.0008
Diabetes Mellitus, Type 2
Primary: Glycated Hemoglobin (HbA1c) (%) — 8.1; 8.0; 7.5; 7.4 Percentage of HbA1c
Type 2 Diabetes Mellitus With Diabetic Nephropathy
Primary: Albuminuria Absolute Value and Ratio to Baseline by Study Visit and Treatment Group — 705.72; 696.30; 758.22; 705.29 mg/g — p=1.000
Thyroid Carcinoma · Thyroid Cancer · Thyroid Cancer, Follicular
Primary: Number of Participants Who Experienced a Dose-limiting Toxicity (DLT) — 0; 0; 0; 0 Participants
Dental Implant Failure Nos
Primary: Percent Change in Volume of Alveolar Ridge as Measured by 3D Intraoral Scanning — 15.5; 16.8 percentage of volume change
Aortic Valve Stenosis · Aortic Valve Failure · Aortic Insufficiency
Primary: Primary Safety Endpoint: The Rate of All-cause Mortality, Disabling Stroke, Life-threatening Bleeding Requiring Blood Transfusion, Acute Kidney Injury (AKI) Requiring…
Dementia
Primary: Frequency of Agitated and Aggressive Behaviors (Staff Report) — 44.1; 47.9 score on a scale — p=<0.05
Dry Eye
Primary: Change From Baseline in Ocular Discomfort — 1.35; 2.07 score on a scale
Microsatellite Stable · Mismatch Repair Protein Proficient · Stage III Colorectal Cancer AJCC v7
Primary: Proportion of Participants With Treatment-related, Dose-limiting Toxicities (DLT) (Safety Lead-In Cohort) — 0.33 proportion of participants
Schizophrenia
Primary: Change in Positive Symptoms of Schizophrenia — 22.6; 24.2 units on a scale
Infections
Primary: Cefazolin Plasma Concentration Following Infusion — 491; 117; 99.7; 57.9 ug/mL